市場調查報告書

神經纖維瘤治療藥市場 - 各疾病類型 (神經纖維瘤1型、神經纖維瘤2型、神經鞘瘤)、流通管道、地區:市場規模、佔有率、展望、機會分析 (2020-2027年)

Neurofibromatosis Treatment Drugs Market, by Disease Type (Neurofibromatosis 1 and Neurofibromatosis 2, and Schwannomatosis), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 968728
出版日期 內容資訊 英文 166 Pages
商品交期: 2-3個工作天內
價格
神經纖維瘤治療藥市場 - 各疾病類型 (神經纖維瘤1型、神經纖維瘤2型、神經鞘瘤)、流通管道、地區:市場規模、佔有率、展望、機會分析 (2020-2027年) Neurofibromatosis Treatment Drugs Market, by Disease Type (Neurofibromatosis 1 and Neurofibromatosis 2, and Schwannomatosis), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年09月21日內容資訊: 英文 166 Pages
簡介

研究開發神經纖維瘤的新治療藥的醫藥品企業及生物科技企業的關注高漲,預計促進在預測期間內的神經纖維瘤治療藥市場成長。

本報告提供全球神經纖維瘤治療藥市場相關調查,市場概要,影響市場的因素分析,各市場區隔、各地區的市場分析,並提供主要企業簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

  • 報告的說明
  • 市場定義和範圍
  • 摘要整理
  • 市場明細:各疾病類型
  • 市場明細:各流通管道
  • 市場明細:各地區
  • Coherent Opportunity Map (COM)

第3章 市場動態、規定、趨勢分析

  • 市場動態
  • 促進因素
  • 阻礙因素
  • 影響分析
  • 市場機會
  • 合作與收購
  • 法規方案

第4章 全球神經纖維瘤治療藥市場:COVID-19大流行的影響

  • COVID-19中的影響
  • COVID-19後的影響
  • 政府的積極推動
  • 對醫療保健產業的整體影響

第5章 全球神經纖維瘤治療藥市場:各疾病類型

  • 簡介
  • 市場佔有率分析
  • 與前一年同期比較成長分析
  • 市場區隔趨勢
    • 神經纖維瘤第一型 (NF1)
    • 神經纖維瘤2型 (NF2)
    • 神經鞘瘤

第6章 全球神經纖維瘤治療藥市場:各流通管道

  • 簡介
  • 市場佔有率分析
  • 與前一年同期比較成長分析
  • 市場區隔趨勢
    • 醫院藥局
    • 零售藥局
    • 線上藥局

第7章 全球神經纖維瘤治療藥市場:各地區

  • 簡介
  • 市場佔有率分析:各國
  • 與前一年同期比較成長分析:各國
  • 北美
    • 簡介
    • 市場規模與預測:各疾病類型
    • 市場規模與預測:各流通管道
    • 市場規模與預測:各國
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第8章 競爭情形

  • 企業簡介
  • AstraZenecaPlc
目錄

Title:
Neurofibromatosis Treatment Drugs Market, by Disease Type (Neurofibromatosis 1 (NF1) and Neurofibromatosis 2 (NF2), and Schwannomatosis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Neurofibromatosis is a genetic disorder of the nervous system. It mainly affects growth of nerve cells. It is characterized by the growth of tumors on nerves. Neurofibromatosis is considered as a hereditary disease which mainly occurs in children or it can happen due to mutation (change) of genes. Usually the Neurofibromatosis tumors are benign, but sometimes they can become cancerous. There are three types of neurofibromatosis: Type 1 (NF1), Type 2 (NF2), and Schwannomatosis. All three types show varied symptoms.

Market Dynamics

The increasing focus of pharma and biotech companies on the research and development of novel treatment drugs for neurofibromatosis is expected to drive the neurofibromatosis treatment drugs market growth during the forecast period. For instance, on July 8, 2020, Nobelpharma initiated phase 3 clinical trial study to evaluate the safety and efficacy of long-term treatment with NPC-12G gel for patients with neurofibromatosis type I. The study is estimated to complete in April 30, 2022.

Key features of the study:

  • This report provides in-depth analysis of the global neurofibromatosis treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global neurofibromatosis treatment drugs market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key company covered as a part of this study includes AstraZeneca Plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global neurofibromatosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurofibromatosis treatment drugs market.

Detailed Segmentation:

  • Global Neurofibromatosis treatment drugs market, By Disease Type:
    • Neurofibromatosis 1 (NF1)
    • Neurofibromatosis 2 (NF2)
    • Schwannomatosis
  • Global Neurofibromatosis treatment drugs market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Neurofibromatosis treatment drugs market , By Region:
    • North America
      • By Disease Type:
      • Neurofibromatosis 1 (NF1)
      • Neurofibromatosis 2 (NF2)
      • Schwannomatosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Disease Type:
      • Neurofibromatosis 1 (NF1)
      • Neurofibromatosis 2 (NF2)
      • Schwannomatosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Disease Type:
      • Neurofibromatosis 1 (NF1)
      • Neurofibromatosis 2 (NF2)
      • Schwannomatosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Disease Type:
      • Neurofibromatosis 1 (NF1)
      • Neurofibromatosis 2 (NF2)
      • Schwannomatosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Disease Type:
      • Neurofibromatosis 1 (NF1)
      • Neurofibromatosis 2 (NF2)
      • Schwannomatosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Disease Type:
      • Neurofibromatosis 1 (NF1)
      • Neurofibromatosis 2 (NF2)
      • Schwannomatosis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profile
    • AstraZeneca *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Disease Type
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Restraints
  • Impact Analysis
  • Market Opportunities
  • Collaborations and Acquisition
  • Regulatory Scenario

4. Global Neurofibromatosis Treatment Drugs Market, Impact of COVID-19 Pandemic

  • During COVID-19 Impact
  • Post COVID-19 Impact
  • Government Initiatives
  • Overall Impact On Healthcare Industry

5. Global Neurofibromatosis Treatment Drugs Market, By Disease Type, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Neurofibromatosis 1 (NF1)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Neurofibromatosis 2 (NF2)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Schwannomatosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

6. Global Neurofibromatosis Treatment Drugs Market, By Distribution Channel, 2016 - 2027, (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017- 2027
  • Segment Trends
    • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)
    • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)
    • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)

7. Global Neurofibromatosis Treatment Drugs Market, By Region, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, By Country, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, For Countries, 2017-2027
  • North America
  • Introduction
  • Market Size and Forecast, By Disease Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, By Disease Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, By Disease Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, By Disease Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, By Disease Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, By Disease Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2016-2027 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Company Profiles
  • AstraZeneca Plc.*
  • Company Overview
  • Disease Type Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies